OBJECTIVES: Clinical practice guidelines recommend at least annual testing of estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (uACR) for patients with chronic kidney ...

The estimated glomerular filtration rate (eGFR) is a blood test to assess kidney function. The formula for calculating eGFR takes the patient’s body size, age, and sex into account to predict how well ...

NK cell expansion after primary multimodal treatment to predict progression free survival in inoperable stage III NSCLC. Management and treatment of patients with stage III unresected NSCLC at UPMC: A ...

"This study shows that it’s feasible to evaluate both response and progression using a simple, relatively inexpensive blood test. It can give the physician and the patient confidence that the therapy ...

Please provide your email address to receive an email when new articles are posted on . 32.2% of Medicare fee-for-service beneficiaries received yearly eGFR and urinary albumin-creatinine ratio ...

In this presentation the speaker will discuss latest developments in NSCLC precision therapy and biomarker landscape, and importance of NGS in NSCLC biomarker testing. He will review the NSCLC ...

Despite the fact that albuminuria represents a key risk factor for chronic kidney disease (CKD), even in the absence of reduced filtration, testing for the condition is low among adult patients with ...

Major differences between eGFR based on cystatin C compared with creatinine were associated with higher rates for all-cause mortality, CV events and kidney failure for outpatients, according to data ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- ...

The FINANCIAL — Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of ...

A pair of late-breaking trials, LAURA and ADRIATIC, promise practice-changing news in lung cancer. The targeted therapy osimertinib (Tagrisso, AstraZeneca) improved progression-free survival (PFS) by ...